{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:18:59Z","timestamp":1787872739364,"version":"build-2784847793"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors (HIF) play an important role in regulation of cellular adaptation to hypoxia. The aim of our study was to investigate single nucleotide polymorphisms (SNPs) in the\n                      <jats:italic>HIF1A<\/jats:italic>\n                      gene coding for the regulatory alpha subunit (HIF-1A) and their role in the response to chemotherapy in patients with MM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      Our retrospective genetic association study included 234 patients with MM, who were treated with a combination of cisplatin\/pemetrexed or cisplatin\/gemcitabine at the Institute of Oncology Ljubljana between January 2001 and September 2018. Selected\n                      <jats:italic>HIF1A<\/jats:italic>\n                      SNPs (rs1154965, rs11549467, and rs2057482) were genotyped using the competitive allele-specific polymerase chain reaction (KASP). Additionally, we used a TaqMan assay for independent confirmation of rs11549465 genotyping results. The impact of the SNPs on response to chemotherapy was analysed using logistic regression. For survival analysis, we used the Kaplan-Meier method and Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In heterozygotes with the\n                      <jats:italic>HIF1A<\/jats:italic>\n                      rs11549465 CT genotype, response to chemotherapy was significantly worse compared to homozygotes with the CC genotype, but only after adjustment for weight loss and CRP (RO\n                      <jats:sub>adj<\/jats:sub>\n                      = 0.37; 95% CI = 0.14\u20130.97; P\n                      <jats:sub>adj<\/jats:sub>\n                      = 0.044).\n                      <jats:italic>HIF1A<\/jats:italic>\n                      rs11549467 and rs2057482 were not associated with response to chemotherapy (all P &gt; 0.05). None of the investigated SNPs were associated with progression-free survival or overall survival (all P &gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Among the investigated\n                      <jats:italic>HIF1A<\/jats:italic>\n                      SNPs, only rs11549465 has showed association with a worse response to chemotherapy after the adjustment for clinical parameters. The findings of this study have improved our understanding of the role of\n                      <jats:italic>HIF1A<\/jats:italic>\n                      polymorphisms in MM and may offer valuable insights into their impact on other cancers as well.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0049","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:25:09Z","timestamp":1757924709000},"page":"403-411","source":"Crossref","is-referenced-by-count":2,"title":["Genetic variability of\n                    <i>HIF1A<\/i>\n                    and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma"],"prefix":"10.2478","volume":"59","author":[{"given":"Matic","family":"Setina","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Setina","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Doljak","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Goricar","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Dolzan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljem","family":"Kovac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2026071215515212912_j_raon-2025-0049_ref_001","doi-asserted-by":"crossref","unstructured":"Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The Influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478\/raon-2018-0004","DOI":"10.2478\/raon-2018-0004"},{"key":"2026071215515212912_j_raon-2025-0049_ref_002","doi-asserted-by":"crossref","unstructured":"Rigon M, Mutti L, Campanella M. Pleural mesothelioma (PMe): the evolving molecular knowledge of a rare and aggressive cancer. Mol Oncol 2024; 18: 797-814. doi: 10.1002\/1878-0261.13591","DOI":"10.1002\/1878-0261.13591"},{"key":"2026071215515212912_j_raon-2025-0049_ref_003","doi-asserted-by":"crossref","unstructured":"R\u00f8e OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 2015; 24: 115-31. doi: 10.1183\/09059180.00007014","DOI":"10.1183\/09059180.00007014"},{"key":"2026071215515212912_j_raon-2025-0049_ref_004","doi-asserted-by":"crossref","unstructured":"McDonald JC, Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev 2021; 30: 200226. doi: 10.1183\/16000617.0226-2020","DOI":"10.1183\/16000617.0226-2020"},{"key":"2026071215515212912_j_raon-2025-0049_ref_005","doi-asserted-by":"crossref","unstructured":"Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004; 14: 469-77, viii. doi: 10.1016\/j. thorsurg.2004.06.011","DOI":"10.1016\/j.thorsurg.2004.06.011"},{"key":"2026071215515212912_j_raon-2025-0049_ref_006","unstructured":"Agency of the Republic of Slovenia for the Environment, Human Health and Ecosystems. [Incidence and mortality of malignant mesothelioma]. [Slovenian]. Ljubljana: ARSO; 2021."},{"key":"2026071215515212912_j_raon-2025-0049_ref_007","doi-asserted-by":"crossref","unstructured":"Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surg Pathol Clin 2020; 13: 73-89. doi: 10.1016\/j.path.2019.10.001.","DOI":"10.1016\/j.path.2019.10.001"},{"key":"2026071215515212912_j_raon-2025-0049_ref_008","doi-asserted-by":"crossref","unstructured":"Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis 2018; 10(Suppl 2): S253-61. doi: 10.21037\/jtd.2017.10.09","DOI":"10.21037\/jtd.2017.10.09"},{"key":"2026071215515212912_j_raon-2025-0049_ref_009","doi-asserted-by":"crossref","unstructured":"Sahu RK, Ruhi S, Jeppu AK, Al-Goshae HA, Syed A, Nagdev S, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol 2023; 13: 1204722. doi: 10.3389\/fonc.2023.1204722","DOI":"10.3389\/fonc.2023.1204722"},{"key":"2026071215515212912_j_raon-2025-0049_ref_010","doi-asserted-by":"crossref","unstructured":"Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 2016; 25: 472-86. doi: 10.1183\/16000617.0063-2016","DOI":"10.1183\/16000617.0063-2016"},{"key":"2026071215515212912_j_raon-2025-0049_ref_011","doi-asserted-by":"crossref","unstructured":"Sayan M, Eren MF, Gupta A, Ohri N, Kotek A, Babalioglu I, et al. Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm. Adv Respir Med 2019; 87: 289-97. doi: 10.5603\/ARM.2019.0051","DOI":"10.5603\/ARM.2019.0051"},{"key":"2026071215515212912_j_raon-2025-0049_ref_012","doi-asserted-by":"crossref","unstructured":"\u0160trbac D, Dol\u017ean V. Novel and future treatment options in mesothelioma: a systematic review. Int J Mol Sci 2022; 23: 1975. doi: 10.3390\/ijms23041975","DOI":"10.3390\/ijms23041975"},{"key":"2026071215515212912_j_raon-2025-0049_ref_013","doi-asserted-by":"crossref","unstructured":"Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16: 923-7. doi: 10.1093\/annonc\/mdi187","DOI":"10.1093\/annonc\/mdi187"},{"key":"2026071215515212912_j_raon-2025-0049_ref_014","doi-asserted-by":"crossref","unstructured":"Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014; 19: 601-6. doi: 10.1007\/s10147-013-0619-5","DOI":"10.1007\/s10147-013-0619-5"},{"key":"2026071215515212912_j_raon-2025-0049_ref_015","doi-asserted-by":"crossref","unstructured":"Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.doi: 10.1056\/NEJMoa1000678","DOI":"10.1056\/NEJMoa1000678"},{"key":"2026071215515212912_j_raon-2025-0049_ref_016","doi-asserted-by":"crossref","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up? Ann Oncol 2022; 33: 129-42. doi: 10.1016\/j.annonc.2021.11.005","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"2026071215515212912_j_raon-2025-0049_ref_017","doi-asserted-by":"crossref","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022; 33: 488-99. doi: 10.1016\/j.an-nonc.2022.01.074","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"2026071215515212912_j_raon-2025-0049_ref_018","doi-asserted-by":"crossref","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF,\u2219van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019; 7: 260-70. doi: 10.1016\/S2213-2600(18)30420-X","DOI":"10.1016\/S2213-2600(18)30420-X"},{"key":"2026071215515212912_j_raon-2025-0049_ref_019","unstructured":"Kova\u010d V. Mezoteliomi. [Slovenian]. Onkologija (Ljubljana) 2012; 16: 64-8, 112."},{"key":"2026071215515212912_j_raon-2025-0049_ref_020","doi-asserted-by":"crossref","unstructured":"Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44. doi: 10.2478\/v10019-012-0032-0","DOI":"10.2478\/v10019-012-0032-0"},{"key":"2026071215515212912_j_raon-2025-0049_ref_021","doi-asserted-by":"crossref","unstructured":"Kim MC, Hwang SH, Kim NY, Lee HS, Ji S, Yang Y, Kim Y. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. BMC Cancer 2018; 18: 819. doi: 10.1186\/s12885-018-4720-z","DOI":"10.1186\/s12885-018-4720-z"},{"key":"2026071215515212912_j_raon-2025-0049_ref_022","unstructured":"Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 2007; 80: 51-60. PMID: 18160990"},{"key":"2026071215515212912_j_raon-2025-0049_ref_023","doi-asserted-by":"crossref","unstructured":"Gladek I, Ferdin J, Horvat S, Calin GA, Kunej T. HIF1A gene polymorphisms and human diseases: graphical review of 97 association studies. Genes Chromosomes Cancer 2017; 56: 439-52.","DOI":"10.1002\/gcc.22449"},{"key":"2026071215515212912_j_raon-2025-0049_ref_024","unstructured":"Lieberman M, Peet A. Marks\u2019 basic medical biochemistry: a clinical approach. 5th edition. Philadelphia: Wolters Kluwer; 2018."},{"key":"2026071215515212912_j_raon-2025-0049_ref_025","doi-asserted-by":"crossref","unstructured":"Taabazuing CY, Hangasky JA, Knapp MJ. Oxygen sensing strategies in mammals and bacteria. J Inorg Biochem 2014; 133: 63-72. doi: 10.1016\/j. jinorgbio.2013.12.010","DOI":"10.1016\/j.jinorgbio.2013.12.010"},{"key":"2026071215515212912_j_raon-2025-0049_ref_026","doi-asserted-by":"crossref","unstructured":"Wu LF, Xu GP, Zhao Q, Zhou LJ, Wang D, Chen WX. The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis. BMC Cancer 2019; 19: 1123. doi: 10.1042\/BSR2019241","DOI":"10.1186\/s12885-019-6329-2"},{"key":"2026071215515212912_j_raon-2025-0049_ref_027","doi-asserted-by":"crossref","unstructured":"Zhang Q, Chen Y, Zhang B, Shi B, Weng W, Chen Z, et al. Hypoxia-inducible factor-1a polymorphisms and risk of cancer metastasis: a meta-analysis. PLoS One 2013; 8: e70961. doi: 10.1371\/journal.pone.0070961","DOI":"10.1371\/journal.pone.0070961"},{"key":"2026071215515212912_j_raon-2025-0049_ref_028","doi-asserted-by":"crossref","unstructured":"Ray SK, Mukherjee S. Hypoxia-inducible factors-based single nucleotide polymorphism in breast cancer with more cancer susceptibility. Curr Mol Med 2023; 23: 285-8. doi: 10.2174\/1566524022666220513124853","DOI":"10.2174\/1566524022666220513124853"},{"key":"2026071215515212912_j_raon-2025-0049_ref_029","doi-asserted-by":"crossref","unstructured":"Zupanc C, Franko A, Strbac D, Kovac V, Dolzan V, Goricar K. The association of genetic factors with serum calretinin levels in asbestos-related diseases. Radiol Oncol 2023; 57: 473-486. doi: 10.2478\/raon-2023-0061","DOI":"10.2478\/raon-2023-0061"},{"key":"2026071215515212912_j_raon-2025-0049_ref_030","doi-asserted-by":"crossref","unstructured":"Wu F, Zhang J, Liu Y, Zheng Y, Hu N. HIF1\u03b1 genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol Biochem 2013; 32: 1566-76. doi: 10.1159\/000356593","DOI":"10.1159\/000356593"},{"key":"2026071215515212912_j_raon-2025-0049_ref_031","doi-asserted-by":"crossref","unstructured":"Chen Q, Tian WJ, Huang ML, Liu CH, Yao TT, Guan MM. Association between HIF-1 alpha gene polymorphisms and response in patients undergoing neoadjuvant chemotherapy for locally advanced cervical cancer. Med Sci Monit 2016; 22: 3140-6. doi: 10.12659\/msm.897486","DOI":"10.12659\/MSM.897486"},{"key":"2026071215515212912_j_raon-2025-0049_ref_032","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang J, Li Z. Association of HIF1-\u03b1 gene polymorphisms with advanced non-small cell lung cancer prognosis in patients receiving radiation therapy. Aging (Albany NY). 2021; 13: 6849-65. doi: 10.18632\/aging.202542","DOI":"10.18632\/aging.202542"},{"key":"2026071215515212912_j_raon-2025-0049_ref_033","doi-asserted-by":"crossref","unstructured":"Khoshinani HM, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy. Cancer Invest 2016; 34: 536-45. doi: 10.1080\/07357907.2016.1245317","DOI":"10.1080\/07357907.2016.1245317"},{"key":"2026071215515212912_j_raon-2025-0049_ref_034","doi-asserted-by":"crossref","unstructured":"Xia Y, Jiang L, Zhong T The role of HIF-1a in chemo-\/radioresistant tumors. Onco Targets Ther 2018; 11: 3003-11. doi: 10.2147\/OTT.S158206","DOI":"10.2147\/OTT.S158206"},{"key":"2026071215515212912_j_raon-2025-0049_ref_035","doi-asserted-by":"crossref","unstructured":"Hao J, Song X, Song B, Liu Y, Wei L, Wang X, et al. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 2008; 15: 449-55. doi: 10.1038\/cgt.2008.4","DOI":"10.1038\/cgt.2008.4"},{"key":"2026071215515212912_j_raon-2025-0049_ref_036","doi-asserted-by":"crossref","unstructured":"Liu B, Liu Q, Song Y, Li X, Wang Y, Wan S, et al. Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery. Med Oncol 2014; 31: 877. doi: 10.1007\/s12032-014- 0877-8","DOI":"10.1007\/s12032-014-0877-8"},{"key":"2026071215515212912_j_raon-2025-0049_ref_037","doi-asserted-by":"crossref","unstructured":"Guo X, Li D, Chen Y, An J, Wang K, Zhuding Xu, et al. SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery. Sci Rep 2015; 5: 11846. doi: 10.1038\/srep11846","DOI":"10.1038\/srep11846"},{"key":"2026071215515212912_j_raon-2025-0049_ref_038","doi-asserted-by":"crossref","unstructured":"Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402. doi: 10.1038\/nrc2867. Correction in Nat Rev Cancer 2010; 10: 523.","DOI":"10.1038\/nrc2867"},{"key":"2026071215515212912_j_raon-2025-0049_ref_039","doi-asserted-by":"crossref","unstructured":"Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, et al. The association between HIF-1\u03b1 polymorphism and cancer risk: a systematic review and meta-analysis. Tumor Biology 2013; 35: 903-16. doi: 10.1007\/s13277-013-1160-x","DOI":"10.1007\/s13277-013-1160-x"},{"key":"2026071215515212912_j_raon-2025-0049_ref_040","doi-asserted-by":"crossref","unstructured":"Li HN, He T, Yong-Jiu Zha, Du F, Liu J, Lin HR, et al. HIF-1a rs11549465 C>T polymorphism contributes to increased cancer susceptibility: evidence from 49 studies. J Cancer 2019; 10: 5955-63. doi: 10.7150\/jca.35716","DOI":"10.7150\/jca.35716"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:47Z","timestamp":1783903187000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,5]]},"published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["10.2478\/raon-2025-0049"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0049","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}